| Prefibrotic PMF | Fibrotic PMF | p value |
---|---|---|---|
Sex | M:F = 11/15 | M:F = 15/31 | n.s. |
Median age at diagnosis (years) | 43 (20–87) | 61 (27–83) | p = 0.019 |
WBC at diagnosis (109/l) | 9100 | 8745 | n.s. |
Hb at diagnosis (g/dl) | 14.6 | 14.3 | n.s. |
PLT at diagnosis (109/l) | 825000 | 797500 | n.s. |
Increased LDH | 6/19 (31.6%) | 19/31 (61.3%) | n.s. |
Splenomegaly (%) | 6 (23%) | 12 (26%) | n.s. |
JAK2V617-positive (%) | 9 (50%) | 14 (58%) | n.s. |
History of thrombosis (%) | 6 (23%) | 10 (22%) | n.s. |
Thrombosis at diagnosis (%) | 4 (15%) | 7 (15%) | n.s. |
Thrombotic events during follow-up (%) | 6 (23%) | 5 (10%) | n.s. |
Progression to overt MF (%) | 0 (0%) | 3 (6.5%) | n.s. |
Dead/Alive | 2/24 | 6/40 | n.s. |
Conventional Risk (Low/High) | 13/13 | 17/29 | n.s. |
Cytoreductive therapy (%) | 24 (92%) | 40 (86%) | n.s. |